Treatment Options for Premenstrual Syndrome (PMS)
Selective serotonin reuptake inhibitors (SSRIs) are the first-line pharmacological treatment for moderate to severe PMS and PMDD, with continuous administration being more effective than luteal phase dosing. 1
First-Line Treatments
Non-Pharmacological Approaches
- Lifestyle modifications (should be recommended for all women with PMS):
Pharmacological Options
SSRIs (first-line for moderate-severe symptoms):
NSAIDs for physical symptoms:
- Ibuprofen 600-800mg every 6-8 hours with food for the first 24-48 hours 3
- Particularly effective for dysmenorrhea and menorrhagia
Calcium supplementation:
- Shown to reduce emotional, behavioral, and physical premenstrual symptoms 4
Second-Line Treatments
Hormonal Contraceptives:
- Combined oral contraceptives (COCs) with ≤35 μg ethinyl estradiol 3
- Benefits include decreased menstrual cramping, blood loss, regulation of cycles 3
- Monophasic COCs with 30-35 μg ethinyl estradiol and levonorgestrel or norgestimate recommended 3
- LNG-IUD may be considered (50% of users experience amenorrhea or oligomenorrhea by 2 years) 3
Other medications:
Treatment Algorithm
For mild symptoms:
- Start with lifestyle modifications (diet, exercise, stress reduction)
- Add calcium supplementation
- Consider NSAIDs for physical symptoms
For moderate symptoms:
- Continue lifestyle modifications
- Add SSRIs (continuous dosing preferred)
- Consider hormonal contraception if SSRIs are ineffective or contraindicated
For severe symptoms (PMDD):
- SSRIs as primary treatment (continuous dosing)
- Consider combination therapy with hormonal contraception
- Cognitive behavioral therapy as adjunct 6
Special Considerations
- Iron supplementation should be considered if bleeding is heavy to prevent anemia 3
- Herbal supplements like chasteberry may provide benefit for some women 6, though evidence is limited
- Ovulation suppression therapies (e.g., GnRH agonists) may be effective but carry risks of low estrogen effects including cardiac and osteoporotic concerns 4
Monitoring and Follow-up
- Regular follow-up after 3 months to assess treatment response 3
- Monitor for adverse effects, particularly with SSRIs
- Consider changing treatment strategy if inadequate response after 3 cycles
Common Pitfalls to Avoid
- Failing to distinguish between PMS and PMDD (PMDD affects 3-8% of reproductive-age women and requires more aggressive treatment) 6
- Not addressing both physical and psychological symptoms
- Overlooking the importance of lifestyle modifications as foundation of treatment
- Using luteal phase SSRI dosing when continuous dosing is more effective 1
- Not providing adequate counseling about expected side effects of medications
Remember that PMS affects 30-40% of reproductive-age women 6, and treatment should address both the physical and psychological symptoms to improve quality of life.